Introduction
============

Serrated polyposis (SPP), which was previously known as hyperplastic polyposis, is characterized by the presence of multiple colorectal epithelial polyps with a serrated architecture, termed serrated (SE) polyps, as well as an increased predisposition to colorectal cancer (CRC) ([@b1-ijmm-38-03-0687]--[@b3-ijmm-38-03-0687]). SE polyps differ from adenomatous (AD) polyps and are comprised of various lesions, namely: hyperplastic polyps (HPs), non-dysplastic lesions with normal proliferation and architecture but elongated crypts with a saw-toothed appearance; sessile serrated adenomas (SSAs), lesions that present abnormal proliferation and architecture and may or may not include dysplasia; and traditional serrated adenomas (TSAs) that are dysplastic polyps with prominent serration ([@b1-ijmm-38-03-0687],[@b4-ijmm-38-03-0687]--[@b6-ijmm-38-03-0687]). The presence of multiple SE polyps has also been associated with other hereditary conditions, namely serrated pathway syndrome or Jass syndrome ([@b7-ijmm-38-03-0687]--[@b9-ijmm-38-03-0687]).

It has been proposed that these SE lesions arise through the serrated pathway rather than through the adenoma-carcinoma sequence pathway ([@b7-ijmm-38-03-0687],[@b10-ijmm-38-03-0687]--[@b13-ijmm-38-03-0687]). It has also been suggested that the HP is the precursor lesion in this pathway, with SSA as an intermediate step which then progresses to an adenocarcinoma with or without microsatellite instability (MSI or MSS, respectively). At the molecular level, SE lesions associated with those hereditary serrated syndromes share some genetic alterations, namely the presence of B-raf proto-oncogene, serine/threonine kinase (*BRAF*) mutations and the methylator phenotype, termed CpG island methylator phenotype (CIMP) ([@b14-ijmm-38-03-0687]--[@b16-ijmm-38-03-0687]), although these are also common to the sporadic SE lesions.

However, the analysis of SPP lesions has revealed specific features which are distinct from the SE lesions occurring in a sporadic context; accordingly, in SPP, HPs, TSAs and CRC are preferentially located in the proximal colon, i.e. proximal to the splenic flexure ([@b17-ijmm-38-03-0687]--[@b19-ijmm-38-03-0687]). Moreover, patients with SPP have previously been found to present extensive DNA methylation in the normal mucosa of the proximal colon ([@b20-ijmm-38-03-0687]), suggesting the involvement of widespread gene promoter methylation (CIMP) ([@b7-ijmm-38-03-0687],[@b14-ijmm-38-03-0687],[@b21-ijmm-38-03-0687]). This phenotype appears to be related to MutL homolog 1 (*MLH1*) methylation, which has been associated with MSI status, rather than O-6-methylguanine-DNA methyltransferase (*MGMT*) methylation. However, MSI appears to be less frequent in SPP lesions than in sporadic lesions ([@b14-ijmm-38-03-0687],[@b22-ijmm-38-03-0687]). Similarly, SPP lesions also exhibited a lower frequency of Kirsten rat sarcoma viral oncogene homolog (*KRAS*) mutations when compared with sporadic SE lesions ([@b21-ijmm-38-03-0687],[@b22-ijmm-38-03-0687]). However, it was also found that most adenomas and CRCs from patients with SPP exhibited a classic morphology and that few of these had *BRAF* or *KRAS* mutations, although SE lesions presented a high frequency of mutations in these genes ([@b22-ijmm-38-03-0687]). Previous research has suggested that tumorigenesis associated with SPP may not necessarily follow the serrated pathway and may follow an alternate pathway, involving TSAs and tubulovillous adenomas (TVAs) as intermediate lesions that progress to MSS adenocarcinomas with *KRAS* mutations or even a traditional pathway with adenomatous polyposis coli (*APC*) mutations as the initiating events ([@b10-ijmm-38-03-0687]).

A review of published case studies of SPP reported that approximately 10--50% of patients with SPP have been described as having a family history of CRC ([@b23-ijmm-38-03-0687]). In agreement with these findings, several studies have described an increased risk of CRC in the first-degree relatives of probands diagnosed with SPP compared with the general population ([@b2-ijmm-38-03-0687],[@b17-ijmm-38-03-0687],[@b18-ijmm-38-03-0687],[@b24-ijmm-38-03-0687]--[@b28-ijmm-38-03-0687]). These studies have contributed to the notion that there are SPP cases where heredity may play a role in the development of CRC and/or polyps. Indeed, another review on this subject reinforces the concept that familial SPP exists and also the importance of defining the genetic basis of familial SPP and of studying these families in a systematic manner ([@b29-ijmm-38-03-0687]).

Thus, in the present study, we aimed to characterize, at the clinical and molecular level, SE and AD lesions from a cohort of patients with SPP who had been stratified into two groups: patients with or without a family history of SPP and/or polyps/CRC in first-degree relatives, in order to elucidate the information available regarding this new SPP entity with an apparent hereditary component.

Patients and methods
====================

Patients and specimens
----------------------

Eighteen patients diagnosed with SPP according to the WHO diagnostic criteria ([@b1-ijmm-38-03-0687]) were included in this study: 12 patients with SPP associated with a family history of SPP and/or polyps/CRC (multiple or diagnosed at a young age) in first-degree relatives (designated herein as SPP-FHP/CRC) (11 index and one affected relative diagnosed simultaneously with the index patient), and 6 index patients without a family history of SPP/polyps/CRC (designated herein as sporadic SPP) from the familial colorectal cancer registry of the Portuguese Institute of Oncology of Lisbon Francisco Gentil (Lisbon, Portugal). No evidence of SPP and/or polyps/CRC was found in the first-degree relatives of the patients with sporadic SPP, either by regular colonoscopy examination or by the absence of symptoms. The patients were classified as presenting a family history of polyps in first-degree relatives (5/11), if at least one relative had been diagnosed with polyps at or under 52 years of age or with \>10 polyps. We cannot exclude the possibility that some of these families, namely PH4 or PH6, may have Jass syndrome instead of SPP, due to the presence of a mixture of AD and SE lesions ([@b7-ijmm-38-03-0687],[@b9-ijmm-38-03-0687]). All patients had developed \>10 lesions prior to the date of recruitment.

Sixty-two lesions were included here: 1 hyperplastic colonic mucosa (HCM), 25 HPs, 8 TSAs, 11 SSAs, 1 adenomatous/serrated (AD/S) carcinoma (Ca), 1 serrated carcinoma (SCa), 8 tubular adenomas (TAs), 2 TVAs and 5 Ca. Two normal colonic mucosa (NCM) samples were also included in this study. Fresh colorectal lesions were obtained from colectomy or colonoscopy specimens from patients who underwent surgery or colonoscopy in the Portuguese Institute of Oncology of Lisbon Francisco Gentil. Sections from corresponding areas of the specimens submitted for diagnosis were divided into two parts: one was snap frozen in liquid nitrogen immediately after resection, while the other was formalin-fixed and paraffin-embedded.

Histological characterization, according to the WHO guidelines ([@b1-ijmm-38-03-0687]), was performed by experienced pathologists (R.F. and P.C.). The study was conducted in accordance with local ethical standards and in agreement with the Helsinki Declaration of 1975, as revised in 1983. Informed consent for diagnosis and additional investigational studies, which may result in improving the knowledge about the pathogenesis of the disease, was obtained from patients included in this study. Moreover, biological material used for DNA isolation was obtained from archival sections from colorectal adenomas and carcinomas specimens, submitted for diagnosis (histological classification) and derived from patients who underwent surgery or colonoscopy in the Portuguese Institute of Oncology of Lisbon Francisco Gentil; only somatic analysis was performed and samples are truly anonymized.

Methods
=======

DNA isolation
-------------

DNA was isolated from fresh-frozen and/or paraffin-embedded tumor tissue and matched normal tissue. DNA was isolated from the paraffin-embedded tissues by proteinase K digestion, which was followed by phenol/chloroform extraction and ethanol precipitation, as previously described ([@b30-ijmm-38-03-0687]). DNA from the fresh frozen tissue was isolated by proteinase K digestion, followed by precipitation with a saturated NaCl solution and ethanol as previously described ([@b31-ijmm-38-03-0687]).

Somatic mutation analysis of the APC gene
-----------------------------------------

*APC* mutation analysis was performed using the protein truncation test (PTT) for exon 15, as previously reported ([@b30-ijmm-38-03-0687]). Briefly, *APC* exon 15 was divided into four overlapping fragments that were amplified by polymerase chain reaction (PCR) and, subsequently, *in vitro* transcription and translation were performed using a TnT T7-coupled reticulocyte lysate system (Promega, Madison, WI, USA). In negative cases, the mutational cluster region was subsequently analyzed by automated sequencing in order to search for missense mutations. For the samples obtained from paraffin-embedded tissues, *APC* mutations were analyzed by single-strand conformational polymorphism (SSCP) or by automated sequencing ([@b32-ijmm-38-03-0687]).

Somatic mutation analysis of catenin beta 1 (CTNNB1)
----------------------------------------------------

Genomic DNA from each tumor sample was amplified by PCR for SSCP analysis of exon 3 of the *CTNNB1* gene. The amplified products were analyzed in a mutation detection enhancement (MDE) gel and visualized by silver staining ([@b33-ijmm-38-03-0687]).

Somatic mutation analysis of the AXIN2 gene
-------------------------------------------

*AXIN2* mutation analysis was performed by amplification of a repetitive sequence containing the (G)~7~, (C)~6~ and (C)~5~ tracts (where a considerable mutation frequency was described) ([@b34-ijmm-38-03-0687]), followed by electrophoresis in 7% polyacrilamide gel containing formamide and urea and visualization by silver staining ([@b33-ijmm-38-03-0687]).

Somatic mutation analysis of BRAF, KRAS and neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) genes
---------------------------------------------------------------------------------------------------------

*BRAF* (exon 15: forward primer 5′-TCATAATGCTTG CTCTGATAGGA-3′; reverse primer 5′-GGCCAAAAATTTAATCAGTGGA-3′, *KRAS* (exon 2: forward primer 5′-GTGTGACATGTTCTAATATAGTCA-3′; reverse primer 5′-GAATGGTCCTGCACCAGTAA) ([@b35-ijmm-38-03-0687]) and *NRAS* (exons 2 and 3-primers were kindly provided by Dr Branca Cavaco), were amplified by PCR. The DNA samples were amplified in a standard PCR buffer (Invitrogen, Waltham, MA, USA). Mutations in these genes were analyzed by automated sequencing.

Sequencing analysis
-------------------

After amplification, PCR products were purified with Illustra GFX™ PCR DNA and Gel Band purification kit (GE Healthcare, Little Chalfont, UK) according to the manufacturer\'s instructions. Sequencing reactions were performed using the BigDye Terminator Cycle Sequencing kit and the respective products were analyzed on the ABI PRISM™ 310 Genetic Analyzer (both from Applied Biosystems, Foster City, CA, USA) using Sequencing Analysis software. The pathogenic relevance of missense variants was evaluated by comparing aminoacid sequences using PolyPhen software (<http://genetics.bwh.harvard.edu/pph/>) and SIFT software (<http://sift.jcvi.org/>).

MSI/loss of heterozygosity (LOH) analysis
-----------------------------------------

MSI status was analyzed using the Bethesda panel of reference markers ([@b36-ijmm-38-03-0687]). Each colonic lesion and paired normal DNA were amplified by PCR for each of the microsatellite markers and analyzed in the ABI Prism™ 310 Genetic Analyzer using GeneScan software (Applied Biosystems). The lesions were classified as MSI-high (H) when showing MSI in two or more of the five markers, MSI-low (L) when MSI was detected in one of the markers, and MSS when none of the markers revealed instability ([@b37-ijmm-38-03-0687]). In cases exhibiting MSI-L, BAT-40 and MYCL markers were also analyzed and the lesions were classified as MSI-H when MSI was detected in \>40% of the 7 markers analyzed; otherwise they were classified as MSI-L, as previousy described ([@b37-ijmm-38-03-0687]).

A total of 4 dinucleotide markers flanking *MGMT* (D10S1703, D10S1676, D10S169 and D10S1651) were analyzed for each colonic lesion and paired normal DNA in order to evaluate the presence of LOH. Each lesion was subsequently scored as demonstrating LOH if the ratio between the areas of the normal and the tumor alleles was \>1.5 or \<0.67.

Regarding the D5S346 marker, LOH was evaluated (and confirmed using the D5S1965 marker) as indicative of loss of the *APC* gene. LOH of D2S123 and D17S250 was also evaluated as described above.

Methylation analysis
--------------------

The analysis of *MGMT* and mismatch repair (MMR) gene promoter methylation was performed by methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) ([@b38-ijmm-38-03-0687]) using the SALSA MS-MLPA KIT ME011 MMR, (MRC-Holland, Amsterdam, The Netherlands). MS-MLPA reactions were performed as described by the manufacturer. The samples were analyzed using GeneScan software on the ABI Prism™ 310 Genetic Analyzer (Applied Biosystems). The results were normalized using MRC Coffalyser MLPA-DAT software v.9.4 (MRC-Holland). A ratio of 0.15 or higher, corresponding to 15% of methylated DNA, was indicative of promoter methylation as described elsewhere ([@b32-ijmm-38-03-0687],[@b39-ijmm-38-03-0687]).

Statistical analysis
--------------------

Fisher\'s exact test (using a two-sided or 2×3 table) and the χ^2^ test (<http://www.quantitativeskills.com/sisa/index.htm>) were used to compare categorical variables, and the Student\'s t-test (<http://www.physics.csbsju.edu/stats/t-test.html>) was used to compared continuous variables. A p-value \<0.05 was considered to indicate a statistically significant difference.

Results
=======

Clinical characterization
-------------------------

[Table I](#tI-ijmm-38-03-0687){ref-type="table"} summarizes the clinical features of the 18 patients included in this study, stratified into two groups: SPP-FHP/CRC and sporadic SPP. The average age at diagnosis (i.e. the age at which they presented symptoms) among our cohort of SPP patients (n=18) was 55±11 years (range 25--80); however, it was significantly higher in the SPP-FHP/CRC group than in the sporadic SPP group \[60±10 years (range 41--80) vs. 46±15 years (range 25--68), p=0.027 (Student\'s t-test)\] ([Table II](#tII-ijmm-38-03-0687){ref-type="table"}).

The number of lesions was higher in the SPP-FHP/CRC group than in the sporadic SPP group (threshold, ≥40 lesions): \[10/12 (83%) vs. 3/6 (50%) patients, respectively\]. With respect to histological features, AD lesions were more frequent in the SPP-FHP/CRC group than in the patients with sporadic SPP \[10/12 (83%) vs. 1/6 (17%), p=0.013\]. Moreover, the patients with SPP-FHP/CRC presented a more heterogeneous spectrum of lesions in comparison with the patients with sporadic SPP. In agreement with these findings, the presence of three or more types of lesions was more frequent in the former group \[9/12 (75%) vs. 1/6 (17%), p=0.032\].

Regarding the location of the lesions in each patient, we observed that whereas some of the patients with SPP presented lesions dispersed uniformly throughout the whole colon, other patients with SPP presented a predominance of lesions in one of the two major segments, proximal or distal. Therefore, a prevalence of proximal or distal location of the lesions was considered when at least 70% of the lesions (majority SE) were located in the proximal or distal colon, respectively. In accordance, a preferential proximal location was observed in 3/12 (25%) of the SPP-FHP/CRC patients and in none of the patients with sporadic SPP (0/5). A preferential distal location was observed in 3/5 (60%) of the sporadic SPP patients and in 5/12 (42%) of the patients with SPP-FHP/CRC.

Molecular characterization
--------------------------

The molecular alterations found in each SPP-FHP/CRC lesion, namely mutations in RAS/RAF and Wnt signaling genes, MSI, *MGMT* and MMR methylation, LOH of *MGMT* locus and LOH at D2S123 and D17S250 markers, are presented in [Table III](#tIII-ijmm-38-03-0687){ref-type="table"}. The spectra of these molecular alterations led us to observe that the somatic mutation/promoter hypermethylation spectra differs between those patients whose lesions were preferentially located in the proximal colon, or distributed throughout the whole colon, and those whose lesions were preferentially located in the distal colon, as shown in [Table IV](#tIV-ijmm-38-03-0687){ref-type="table"}. This led us to stratify the patients with SPP-FHP/CRC into two groups, proximal/whole-colon and distal SPP-FHP/CRC.

Although the ratio between the different types of lesions in the two groups, proximal/whole-colon and distal, do not match, i.e. in the former a higher proportion of AD lesions have been analyzed \[in a recent study, individuals with large and right-sided SE lesions also had significantly more AD lesions compared with those without such types of SE lesions ([@b40-ijmm-38-03-0687])\], we found differences with respect to the mutation spectrum, even considering only HPs or SSAs, which have been analyzed in both groups. Accordingly, HPs and SSAs from patients with proximal/whole-colon SPP-FHP/CRC presented RAS/RAF gene mutations less frequently \[2/6 (33%) and 1/7 (14%) vs. 14/14 and 2/2, respectively, p=0.003 and p=0.08\] whereas MMR gene methylation or LOH of D2S123 \[flanking mutS homolog 6 (*MSH6*)\] occurred more frequently (4/4 and 2/2 vs. 0/7 and 0/2, respectively, p=0.003 and p=0.33), when compared with the same type of lesions from distal SPP-FHP/CRC patients ([Table V](#tV-ijmm-38-03-0687){ref-type="table"}). Moreover, SE and AD lesions presented a similar spectrum of molecular alterations, especially among each patient. The exception were *BRAF* mutations that were significantly more frequent in SE lesions \[17/36 (47%) vs. 2/14 (14%), p=0.05\] ([Table V](#tV-ijmm-38-03-0687){ref-type="table"}). For each patient, either presenting proximal/whole-colon or distal SPP-FHP/CRC, the spectra of somatic molecular alterations detected in the lesions were similar regardless of the location of each specific lesion. For example, in a patient with a prevalence of proximal lesions, these presented a specific mutation pattern that was shared by the few distal lesions that were analyzed from the same patient and different from the proximal lesions from patients with a predominance of distal lesions and vice versa (Table IIIA).

The abovementioned findings led us to analyze the molecular data from the patients with SPP-FHP/CRC, who were stratified into two groups: proximal/whole-colon and distal SPP-FHP/CRC.

Proximal/whole-colon vs. distal SPP-FHP/CRC
-------------------------------------------

Mutations in the Wnt genes, as well as MSI, were significantly more frequent in the patients with proximal/whole-colon SPP-FHP/CRC than in the patients with distal SPP-FHP/CRC \[14/26 (54%) vs. 4/20 (20%), p=0.02; 15/26 (58%) vs. 2/15 (13%), p=0.0059\] ([Table IV](#tIV-ijmm-38-03-0687){ref-type="table"}). Interestingly, among the proximal/whole-colon SPP-FHP/CRC samples, Wnt gene mutations were significantly more frequent in the SE lesions than in the AD lesions \[12/16 (75%) vs. 2/10 (20%), p=0.0091\]. In the SE lesions, Wnt gene mutations, as well as MSI, were more frequent in TSAs (4/4 and 3/4) and in SSAs (6/7 and 6/7) and rarely detected in HPs (1/4 and 1/5) (p=0.02 and p=0.017, respectively) ([Table V](#tV-ijmm-38-03-0687){ref-type="table"}).

Similarly, LOH of the *MGMT* locus and *MGMT* methylation were also more frequent in lesions from the patients with proximal/whole-colon SPP-FHP/CRC, in comparison with lesions from the patients with distal SPP-FHP/CRC \[16/23 (70%) vs. 1/14 (7%), p=2.2×10^−4^; 19/29 (65%) vs. 7/17 (41%), p=0.1, respectively\] ([Table IV](#tIV-ijmm-38-03-0687){ref-type="table"}). The same difference was observed even considering SE lesions only ([Table V](#tV-ijmm-38-03-0687){ref-type="table"}). In particular, *MGMT* methylation was detected in all HP lesions (6/6) from proximal/whole-colon SPP-FHP/CRC, in contrast to the lower frequency observed in HPs from distal SPP-FHP/CRC (4/11, 36%) (p=0.017).

Interestingly, among lesions which were deemed informative for methylation analysis and loss of LOH of D2S123, the presence of MMR gene methylation or of the D2S123 LOH (flanking *MSH6*) was only observed in proximal/whole-colon SPP-FHP/CRC lesions \[17/18 (94%) vs. 0/11, p=3.0×10^−7^\]. These alterations were found in the majority of early lesions and in all histological types (Tables IIIA and IV). It is of note that *MLH1* methylation was not detected in any of the SPP-FHP/CRC lesions, being observed only in one lesion from the sporadic SPP group (Table IIIB). Moreover, it is also of note that except for one lesion, MSI, either MSI-L or MSI-H was detected only in dinucleotide microsatellite markers.

By contrast to the abovementioned molecular alterations, in the SPP-FHP/CRC samples, *BRAF* and *KRAS* mutations were more frequent in the lesions located in the distal colon than those located in the proximal/whole-colon \[12/20 (60%) vs. 7/30 (23%), p=0.0089 (χ^2^ test) and 6/20 (30%) vs. 5/32 (16%), respectively\], although the latter was not statistically significant ([Table IV](#tIV-ijmm-38-03-0687){ref-type="table"}). Considering only the SE lesions, mutations in the RAS/RAF genes were detected in all the lesions from the distal SPP-FHP/CRC, namely in all HPs (14/14), HCM (1/1) and in one NCM (Table IIIA), but in only 8/19 (42%) lesions from the proximal/whole-colon SPP-FHP/CRC (p=1.3×10^−4^).

With respect to *KRAS/BRAF* mutations, two groups of patients were observed among those with either proximal/whole-colon or distal SPP-FHP/CRC: one group whose lesions presented *KRAS* mutations (PH4, PH5, PH7 and PH14) and another group, whose lesions presented *BRAF* mutations (PH3, PH8, PH19 and PH33) (Table IIIA). One patient presented either *BRAF*- or *KRAS*-positive lesions (family PH6). Notably, CRC was more frequent in the patients with proximal/whole-colon SPP-FHP/CRC associated with *KRAS* mutations than in the remaining patients \[4/4 vs. 1/8 (12%), p=0.01\] (Tables I and IIIA).

Discussion
==========

SPP-FHP/CRC and sporadic SPP differ at the clinical level
---------------------------------------------------------

The patients with SPP-FHP/CRC and sporadic SPP differed with respect to clinical and histological features. The older mean age at diagnosis (60 vs. 46 years old) of the former may underlie a slower process of tumorigenesis. This is in contrast to that which has been observed in relation to other hereditary CRC syndromes, namely in familial adenomatous polyposis and in Lynch syndrome, which are diagnosed at an earlier age (usually ≤50 years old) compared to the age at diagnosis in patients with sporadic CRC (\>60 years old) ([@b32-ijmm-38-03-0687],[@b41-ijmm-38-03-0687]). The presence of a more heterogeneous histological pattern of lesions in patients with SPP-FHP/CRC, associated with the concomitant presence of both SE and AD lesions, compared with the lesions in patients with sporadic SPP, suggests the involvement of other pathways in the tumorigenic process associated with SPP-FHP/CRC, in addition to the serrated pathway of tumorigenesis.

Molecular alterations involved in tumor initiation distinguish between two forms of SPP-FHP/CRC: proximal/whole-colon and distal
--------------------------------------------------------------------------------------------------------------------------------

Two forms of SPP-FHP/CRC appear to exist according to the preferential location of the lesions in the colon and rectum, proximal/whole-colon and distal, which differ with respect to the somatic events involved in tumor initiation. LOH and methylation of *MGMT*, MMR gene methylation and/or LOH of D2S123 and Wnt gene mutations appear to be the major somatic events that lead to tumor initiation in proximal/whole-colon SPP-FHP/CRC. By contrast, in distal SPP-FHP/CRC, *KRAS* or *BRAF* mutations were found in the majority of early lesions and thus seem to play a major role in tumor initiation.

We have previously shown that distinct Wnt gene mutations are selected in sporadic and hereditary CRC according to tumor location, i.e. proximal or distal colon ([@b33-ijmm-38-03-0687],[@b42-ijmm-38-03-0687]). We and others have also proposed that this finding is the result of the selection of a specific level of β-catenin signaling, optimal for tumor formation, which differs along the colorectum, thus contributing to differences in lesion distribution in specific types of CRC, such as Lynch syndrome ([@b42-ijmm-38-03-0687],[@b43-ijmm-38-03-0687]). Proving this, variable gradients in the number of stem cells and physiological Wnt activity have been demonstrated throughout the length of the intestinal tract ([@b44-ijmm-38-03-0687]). Thus, in a similar fashion, tumorigenic pathways may also differ between proximal and distal SPP-FHP/CRC.

MGMT and MMR alterations, followed by Wnt gene mutations, are involved in the initiation of proximal/whole-colon SPP-FHP/CRC
----------------------------------------------------------------------------------------------------------------------------

The exclusive detection of MMR gene methylation (mainly of *MSH6*) and/or LOH of D2S123 (flanking *MSH6*) in proximal/whole-colon SPP-FHP/CRC, in the majority of early lesions and in all histological types, appears to suggest that the MMR system plays an important role in the initiation of proximal/whole-colon SPP-FHP/CRC, which is in agreement with the high frequency of MSI (either MSI-L or MSI-H) in these lesions (58%). Interestingly, MMR methylation and, consequently, MMR deficiency were not associated with *MLH1* methylation as has been previously observed in sporadic SE lesions located in the proximal colon ([@b7-ijmm-38-03-0687]), but rather with *MSH6* or mutS homolog 3 (*MSH3*) methylation. Accordingly, a high frequency of LOH of the *MSH3* locus has been recently described in sporadic MSI-L CRC, suggesting that the impairment of other MMR genes such as *MSH3* or *MSH6*, as observed in the present study, are involved in an MSI-L pathway, instead of *MLH1*, which is usually associated with the MSI-H serrated pathway ([@b45-ijmm-38-03-0687]). The detection of MSI almost exclusively in dinucleotide microsatellite markers is in agreement with this finding, since this type of MSI has been described to be a characteristic feature of MSI-L tumors ([@b46-ijmm-38-03-0687]). Interestingly, in the present study, MSI was detected more frequently at D2S123 followed by D17S250.

*MGMT* methylation and LOH of the *MGMT* locus were the most frequent alterations in proximal/whole-colon SPP-FHP/CRC, and *MGMT* methylation was detected in all HPs, commonly known as the precursor lesion ([@b12-ijmm-38-03-0687]). Therefore, we suggest that, similarly to MMR alterations, LOH and methylation of *MGMT* may also be early events in SPP-FHP/CRC proximal/whole-colon tumorigenesis. Notably, among the 17 lesions informative for both MMR and *MGMT* alterations in this form of SPP-FHP/CRC, in 16 (94%) both events were noted (Table IIIA). It is known that *MGMT* deficiency results in the inability to repair O6-methylguanine in the DNA, caused by genotoxic stress, which, once accumulated, leads to the translocation of the MutSα complex (MSH2 and MSH6) into the nucleus, thus increasing GT mismatch binding activity ([@b47-ijmm-38-03-0687]). This may lead to a selective pressure for molecular changes that impair MSH2 or MSH6 function such as promoter hypermethylation or LOH, thus explaining the association between the latter and *MGMT* methylation in the same early SPP-FHP/CRC lesions. Thus, we suggest a primary role for *MGMT* methylation, O6-methylguanine errors and MMR alterations in tumor initiation of proximal/whole-colon SPP-FHP/CRC. We further suggest that this molecular signature may indicate that a germline defect in the mechanisms regulating the response to genotoxic stress underlies the genetic susceptibility in this form of SPP-FHP/CRC.

In the present study, the higher frequency of Wnt gene mutations in proximal SPP-FHP/CRC, particularly in SE lesions, when compared with the AD lesions, suggests that this pathway also plays an important role in this form of SPP-FHP/CRC, especially in the transition to SE adenoma since this frequency was significantly higher in TSA and SSA than in HP and HCM (p=8.4×10^−4^). In agreement, *CTNNB1* or *AXIN2* mutations, that are selected almost exclusively in proximal colorectal tumors with MSI ([@b33-ijmm-38-03-0687]), were detected in 4/14 (28%) TSAs and SSAs from proximal/whole-colon SPP-FHP/CRC. Moreover, among *APC* nonsense and missense mutations, the majority (7/8; 88%) were of the transition type which is a characteristic feature of cells presenting MMR defects ([@b48-ijmm-38-03-0687]--[@b50-ijmm-38-03-0687]).

The occurrence of LOH of D2S123 and/or D17S250 dinucleotide marker in the present study \[17/48 (35%) and 7/51 (14%), respectively\], has been previously described in Paneth cell metaplasia, a condition that is commonly observed in the small intestine and the proximal colon of elderly individuals ([@b51-ijmm-38-03-0687],[@b52-ijmm-38-03-0687]). Therefore, *MGMT* deficiency may make these cells more exposed to genotoxic stress, thus leading to molecular changes in Wnt genes and consequently to commitment to Paneth cell lineage \[to which Wnt gene mutations largely contribute ([@b53-ijmm-38-03-0687])\] and to Paneth cell metaplasia. Therefore, colonic mucosa with Paneth cell metaplasia may be one of the pre-neoplastic lesions in the development of proximal/whole-colon SPP-FHP/CRC.

BRAF and KRAS mutations play different roles in proximal and distal SPP-FHP/CRC
-------------------------------------------------------------------------------

Our finding that patients with proximal/whole-colon or distal SPP-FHP/CRC may carry, preferentially, either *KRAS* or *BRAF* mutations, supports previous observations suggesting that different forms of SPP exist, depending on whether lesions follow a KRAS or a BRAF pathway ([@b22-ijmm-38-03-0687]).

In addition, in the present study, we noted distinct roles for these mutations between proximal and distal SPP-FHP/CRC. *BRAF* or *KRAS* mutations were detected in the majority of distal SPP-FHP/CRC lesions, mostly SE early lesions, thus underlining their importance in early stages, whereas in proximal/whole-colon SPP-FHP/CRC these mutations (mainly of *KRAS*) appear to be more important in tumor progression (mostly detected in TSAs, TVAs and Cas). Accordingly, a KRAS or alternate pathway has been proposed to be involved in the transition from TSA or TVA to CRC in SPP ([@b10-ijmm-38-03-0687]). Indeed, in patients with proximal/whole-colon SPP-FHP/CRC, *KRAS* mutations were found only in TSAs, TVAs or Cas (PH4, PH5 and PH7) which is in accordance with their association with the development of a villous architecture and hence with malignant transformation ([@b10-ijmm-38-03-0687],[@b54-ijmm-38-03-0687]--[@b56-ijmm-38-03-0687]). Therefore, as TSAs and TVAs shared early somatic events with HPs and TAs, respectively, from the same patients, and based on the model of SPP tumorigenesis previously presented by Leggett and Whitehall ([@b10-ijmm-38-03-0687]), we propose that proximal/whole-colon SPP-FHP/CRC tumorigenesis may follow an alternate or KRAS pathway, where TVA and TSA may develop from TA and HP, respectively, finally leading to CRC, that may or may not present with MSI ([Fig. 1A](#f1-ijmm-38-03-0687){ref-type="fig"}, upper panel). Alternatively, a serrated or BRAF pathway (families PH3 and PH8) where SSA or TSA will probably lead to MSI-H cancer carrying *BRAF* mutations may also occur ([Fig. 1B](#f1-ijmm-38-03-0687){ref-type="fig"}, upper panel). In this model, a deficient DNA repair pathway characterized by *MGMT* and MMR gene methylation and/or LOH followed by Wnt gene mutations, appears to be predominant in proximal SPP-FHP/CRC ([Fig. 1](#f1-ijmm-38-03-0687){ref-type="fig"}, upper panel).

In distal SPP-FHP/CRC, either *KRAS* (PH6 and PH14) or *BRAF* (PH6, PH12, PH19 and PH33) mutations play a major role in tumor initiation, either through an alternate or a serrated pathway ([Fig. 1A and B](#f1-ijmm-38-03-0687){ref-type="fig"}, bottom panel, respectively). Wnt gene mutations and MMR defects were detected in the only carcinoma presented by these patients and thus are likely involved in tumor progression. As PH6 and PH33 also presented TAs and did not present TVAs, we hypothesize that, in distal SPP-FHP/CRC, some AD lesions may also develop through a traditional pathway initiated by *APC* mutations ([Fig. 1C](#f1-ijmm-38-03-0687){ref-type="fig"}, bottom panel).

CRC is more frequent in patients with proximal/whole-colon SPP-FHP/CRC with TSAs, TVAs and KRAS mutations
---------------------------------------------------------------------------------------------------------

The association of *KRAS* mutations in TSA or TVA with the development of CRC in proximal/whole-colon SPP-FHP/CRC suggests a higher contribution of the alternate pathway in the development of CRC in patients with SPP-FHP/CRC. Supporting our hypothesis, *KRAS* mutations have been previously described as more prevalent than *BRAF* mutations in a series of SE carcinomas occurring in the sporadic context, mainly in those presenting adjacent serrated adenomas (51%) ([@b57-ijmm-38-03-0687]). Moreover, in the same study, SE carcinomas were frequently MSS and presented a higher frequency of *MGMT* loss compared with traditional carcinomas, which is in agreement with our findings demonstrating that *MGMT* deficiency plays a prominent role in SPP-FHP/CRC, mainly in the proximal colon.

The findings that *KRAS* and *BRAF* mutations promote serrated and hyperplastic features, despite being incapable of initiating colonic adenoma development by themselves ([@b58-ijmm-38-03-0687],[@b59-ijmm-38-03-0687]), may contribute to the apparent lower incidence of CRC in distal SPP-FHP/CRC, as according to the results of our present study, *KRAS* or *BRAF* mutations appear to be the initial molecular events in this form. However, additional studies involving more families are warranted.

In conclusion, SPP-FHP/CRC appears to be a distinct clinical and histological entity differing from sporadic SPP. However, we suggest that two forms of SPP-FHP/CRC appear to exist, proximal/whole-colon and distal, which differ mainly in the molecular alterations detected in early lesions. We further propose that a germline defect in the mechanisms regulating the response to genotoxic damage may underlie the genetic susceptibility in the former. In addition, our results suggest that CRC appears to develop more frequently in proximal/whole-colon SPP-FHP/CRC following an alternate KRAS pathway, thus underlining the importance of a complete clinical, histological and molecular characterization for CRC risk evaluation in further studies involving families with SPP. The results of these studies may be used to design appropriate guidelines for the clinical management of proximal and distal colonic presentations of SPP that assumes major relevance considering the increased risk of CRC and/or polyps in first-degree relatives.
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![Proposed pathways for colorectal tumorigenesis in proximal/whole-colon (upper panel) and distal serrated polyposis (SPP) associated with a family history of SPP and/or polyps/colorectal cancer (SPP-FHP/CRC) (bottom panel). Both of these forms may follow a KRAS (alternate) or a BRAF (serrated) pathway, (A and B), respectively, in the upper and lower panels. In addition, in distal SPP, an adenomatous polyposis coli (APC) (traditional) pathway may also occur \[(C) in bottom panel\]. Each lesion or molecular alteration in these proposed pathways is hypothesized based on the results obtained in the present study and we do not exclude that, in some cases, some of these molecular alterations may not occur, or even that other molecular alterations may also be found. The steps involving lesions that were not analyzed in this study and about which we have previously published information are represented by broken arrows. In some pathways a broken line was used to represent the increase in microsatellite instability (MSI) with tumor progression, to suggest a lower frequency in those cases. Ca, carcinoma; H P, hyperplastic polyp; MMR, mismatch repair; SSA, sessile serrated adenoma; TA, tubular adenoma; TSA, traditional serrated adenoma; TVA, tubulovillous adenoma.](IJMM-38-03-0687-g00){#f1-ijmm-38-03-0687}

###### 

Clinical features of the patients evaluated in this study, histological characterization of the respective lesions and family history of SPP and/or polyps/CRC in first-degree relatives.

  Family         Patient ID   Age at diagnosis in years   Gender   Total number of lesions                                                     Type of lesions[a](#tfn1-ijmm-38-03-0687){ref-type="table-fn"}   Preferential location of lesions[b](#tfn2-ijmm-38-03-0687){ref-type="table-fn"}   CRC                                                  WHO diagnostic criteria[c](#tfn3-ijmm-38-03-0687){ref-type="table-fn"}   No. of affected individuals in the family   Family history[d](#tfn4-ijmm-38-03-0687){ref-type="table-fn"} (age at diagnosis in years)
  -------------- ------------ --------------------------- -------- --------------------------------------------------------------------------- ---------------------------------------------------------------- --------------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------
  SPP-FHP/CRC                                                                                                                                                                                                                                                                                                                                                                                                                                                               
   PH1           A756         62                          M        \>100                                                                       **HP**+TALGD+TSALGD+SSA                                          Whole colon[e](#tfn5-ijmm-38-03-0687){ref-type="table-fn"}                        No                                                   3                                                                        3                                           Son, \>45 SE polyps ([@b42-ijmm-38-03-0687]); Son, 2 SE polyps ([@b37-ijmm-38-03-0687])
   PH3           A755         41                          F        \>100                                                                       **HP+TSALGD**+TVALGD+SSA+TALGD                                   Whole colon[e](#tfn5-ijmm-38-03-0687){ref-type="table-fn"}                        No                                                   3                                                                        3                                           Mother, CRC (67); maternal aunt, CRC ([@b58-ijmm-38-03-0687])
   PH4           CA638        66                          M        19                                                                          **TSA** (**LGD+HGD**)+VA                                         Whole colon                                                                       Yes[f](#tfn6-ijmm-38-03-0687){ref-type="table-fn"}   1                                                                        5                                           Twin brother, 20 AD and SE polyps (70); son, 2 AD polyps ([@b37-ijmm-38-03-0687]); nephew, 18 AD polyps ([@b54-ijmm-38-03-0687])
  CA636          69           M                           50       **HP**+TALGD+TSALGD+TVALGD[g](#tfn7-ijmm-38-03-0687){ref-type="table-fn"}   Proximal                                                         Yes[f](#tfn6-ijmm-38-03-0687){ref-type="table-fn"}                                3                                                                                                                                                                         
   PH5           A193         69                          F        40                                                                          **HP**+TALGD+TVAHGD                                              Proximal                                                                          Yes                                                  3 plus 1                                                                 3                                           Sister, 2 AD polyps (67); son, 1 SE polyp ([@b52-ijmm-38-03-0687])
   PH6           A478         64                          M        50--100                                                                     **HP+TSALGD**+TALGD+SSA                                          Distal[e](#tfn5-ijmm-38-03-0687){ref-type="table-fn"}                             No                                                   3 plus 1                                                                 5                                           Father, CRC ([@b57-ijmm-38-03-0687]); sister, 7 polyps (61); daughter, 1 SE polyp ([@b39-ijmm-38-03-0687]); son, 2 AD polyps ([@b35-ijmm-38-03-0687])
   PH7           A759         50                          M        50--100                                                                     **HP**+TA                                                        Whole colon                                                                       Yes                                                  3                                                                        3                                           Mother, 2 AD polyps (75); brother, 8 SE and AD polyps ([@b47-ijmm-38-03-0687])
   PH8           A760         59                          F        45                                                                          **HP+SSA**+TSALGD                                                Proximal                                                                          No                                                   1 plus 3                                                                 4                                           Maternal grandfather, CRC; mother, CRC (73); sister, 3 AD polyps (61)
   PH12          A758         57                          M        40                                                                          **HP**                                                           Distal                                                                            Yes                                                  3                                                                        2                                           Brother, 1 AD polyp ([@b44-ijmm-38-03-0687])
   PH14          A686         80                          M        49                                                                          **HP**+TSALGD+TALGD                                              Distal                                                                            No                                                   3                                                                        4                                           Daughter, 2 SE polyps ([@b54-ijmm-38-03-0687]); daughter, 11 SE and 1 AD polyps ([@b42-ijmm-38-03-0687]); son, 1 AD polyp ([@b44-ijmm-38-03-0687])
   PH19          A993         58                          F        17                                                                          **HP**+TALGD                                                     Distal                                                                            No                                                   1                                                                        3                                           Mother, CRC; sister, 6 polyps (68)
   PH33          A983         49                          M        45                                                                          HP+TSALGD+TALGD+SSA                                              Distal                                                                            No                                                   1 plus 3                                                                 4                                           Paternal uncle, polyps (69); father, 1 AD polyp (77); brother, 1 AD polyp ([@b50-ijmm-38-03-0687])
  Sporadic SPP                                                                                                                                                                                                                                                                                                                                                                                                                                                              
   PH9           A500         48                          F        40                                                                          HP+SSA+TSALGD                                                    Whole colon                                                                       No                                                   1 plus 3                                                                 1                                           \-[h](#tfn8-ijmm-38-03-0687){ref-type="table-fn"}
   PH10          A989         25                          F        \<100                                                                       **HP**                                                           NA                                                                                Yes                                                  3 plus 1                                                                 1                                           \-[h](#tfn8-ijmm-38-03-0687){ref-type="table-fn"}
   PH11          A757         53                          M        50                                                                          **HP+TSA**                                                       Distal                                                                            Yes[f](#tfn6-ijmm-38-03-0687){ref-type="table-fn"}   3                                                                        1                                           \-[h](#tfn8-ijmm-38-03-0687){ref-type="table-fn"}
   PH16          A990         68                          M        15                                                                          **HP**+SSA                                                       Whole colon                                                                       No                                                   1                                                                        1                                           \-[h](#tfn8-ijmm-38-03-0687){ref-type="table-fn"}
   PH18          A992         46                          F        10                                                                          **TSALGD+HP**                                                    Distal                                                                            No                                                   1                                                                        1                                           \-[h](#tfn8-ijmm-38-03-0687){ref-type="table-fn"}
   PH22          A951         33                          F        31                                                                          **HP**+TALGD                                                     Distal                                                                            No                                                   1 plus 3                                                                 1                                           \-[h](#tfn8-ijmm-38-03-0687){ref-type="table-fn"}

The type of lesion(s) that was prevalent (≥70%) in each patient is indicated in bold.

We considered a proximal or distal preferential location of the lesions when at least 70% of the lesions (majority serrated) were located in the proximal or distal colon, respectively.

WHO clinical criteria for the identification of serrated polyposis (SPP), as revised in 2010: i) At least five serrated polyps proximal to the sigmoid colon, two of which are greater than 10 mm in diameter. ii) Any number of serrated polyps occurring proximal to the sigmoid colon in an individual who has a first-degree relative with SPP iii) More than 20 serrated polyps of any size distributed throughout the colon.

AH families showed a dominant inheritance pattern with the exception of PH12, that revealed a recessive pattern.

The polyps are larger in the proximal colon.

Adenomatous/serrated carcinoma (AD/S);

with areas of traditional serrated adenoma (TSA).

No evidence of SPP and/or polyps/CRC was found in first-degree relatives of the sporadic SPP patients, either by regular colonoscopy examination or by absence of symptoms. CRC, colorectal cancer; M, male; F, female; HP, hyperplastic polyp; TALGD, tubular adenoma with low grade dysplasia; TSALGD, traditional serrated adenoma with low grade dysplasia; TVAHGD, tubulovillous adenoma with high grade dysplasia; SSA, sessile serrated adenoma; SE, serrated; TVALGD, tubulovillous adenoma with low grade dysplasia; LGD, low grade dysplasia; HGD, high grade dysplasia; VA, villous adenoma; AD, adenomatous; TA, tubular adenoma; NA, not available; FHP, family history of SPP.

###### 

Comparison between clinical features in patients with sporadic SPP and those with SPP-FHP/CRC.

  Clinical feature                   SPP-FHP/CRC       Sporadic SPP    p-value
  ---------------------------------- ----------------- --------------- -----------------------------------------------------------
  Age at diagnosis (years)           **60±10**         **46±15**       **0.027** (Student\'s t-test)
  Preferential location of lesions                                     
   Whole colon                       4/12 (33%)        2/5 (40%)       NS
   Proximal                          3/12 (25%)        0/5             NS
   Distal                            5/12 (42%)        3/5 (60%)       NS
  ≥40 lesions                        10/12 (83%)       3/6 (50%)       NS
  AD lesions                         **10/12 (83%)**   **1/6 (17%)**   **0.013[a](#tfn10-ijmm-38-03-0687){ref-type="table-fn"}**
  ≥3 types of lesions                **9/12 (75%)**    **1/6 (17%)**   **0.032[a](#tfn10-ijmm-38-03-0687){ref-type="table-fn"}**

Statistically significant values are shown in bold. NS, non-significant (p\>0.05).

Fisher\'s exact test (two-sided). AD, adenomatous; SPP, serrated polyposis; SPP-FHP/CRC, SPP associated with a family history of SPP and/or polyps/colorectal cancer (CRC) (multiple or diagnosed at a young age) in first-degree relatives.

###### 

Results of the molecular analysis of SE and AD lesions from patients with SPP.

  A, Results of the molecular analysis of SE and AD lesions from patients SPP-FHP/CRC                                                                                                                                                                                                                                                                        
  ------------------------------------------------------------------------------------- ----------- ---------- ---------- ----------------- ------------- ------------------------------------- ---------------------------- ----------------------- ---------------------- --------------------------- ---------------------- -------------------- -------- ----------
  Preferential location of lesions - proximal/whole-colon                                                                                                                                                                                                                                                                                                    
   PH1                                                                                  A756        A756AS     TSALGD     NA                MSS′          NC, NC                                Yes                          c.4099C\>T (p.Q1367X)   N                      N                           --                     N                    M        *MSH6*
  A756AT1                                                                               TALGD       NA         MSS′       NC, N             No            c.4123C\>T (p.H1375Y)                 N                            N                       N                      N                           M                      *MSH6*                        
  A756AT2                                                                               TALGD       NA         MSS′       NC, N             IC            c.4123C\>T (p.H1375Y)                 N                            N                       N                      N                           NM                     NM                            
  A756PH1                                                                               HP          NA         MSS′       NC, NC            Yes           N                                     N                            **--**                  N                      N                           M                      *MSH6, MSH3*                  
  A756PH2                                                                               SSA         NA         MSS′       NC, N             IC            c.4289delC (p.T1430TfsX43)            N                            N                       **--**                 N                           M                      *MSH6*                        
   PH3                                                                                  A755        A755AS1    TSALGD     Distal            MSI-H         NI, D17S250                           IC                           NC                      N                      N                           c.1785T\>G (p.F595C)   N                    **--**   ***--***
  A755AS2                                                                               TSA         Proximal   MSI-L      NI, D17S250       IC            c.4235G\>A (p.G1412E)                 c.115G\>A (p.A39T)           N                       c.1799T\>A (p.V600E)   N                           M                      *MSH6*                        
  A755AS3                                                                               TSALGD      Proximal   MSI-H      NI, NI            Yes           NC                                    N                            N                       N                      N                           NM                     *MSH6*                        
  A755PH1                                                                               HP          Proximal   MSI-L      NI, D17S250       Yes           N                                     N                            N                       N                      N                           M                      *MSH6*                        
  A755PH2                                                                               SSA         Proximal   MSI-L      D2S123, D17S250   IC            N                                     N                            N                       N                      N                           NM                     NM                            
   PH4                                                                                  CA638       CA638AS    TSALGD     Distal            MSS           N, N                                  No                           N                       c.122C\>T (p.T41I)     N                           N                      c.35G\>C (p.G12A)    M        *MSH3*
  CA638C                                                                                Ca (AD/S)   Rectum     MSS        N, N              No            LOH                                   N                            N                       N                      c.35G\>A (p.Gl2D)           M                      NM                            
  CA636                                                                                 CA636AT1    TALGD      Proximal   MSI-L             NI, D17S250   Yes                                   c.4262delG (p.S1421MfsX52)   N                       **--**                 N                           N                      M                    NM       
  CA636C                                                                                Ca          Proximal   MSS        D2S123, N         Yes           NC                                    N                            N                       N                      N                           M                      *MLH3*                        
  CA636AT2                                                                              TALGD       Proximal   MSI-L      D2S123, NI        Yes           N                                     N                            N                       N                      N                           NM                     NM                            
  CA636AT3                                                                              TALGD       Proximal   MSS        D2S123, D17S250   Yes           N                                     N                            N                       c.1811G\>A (p.W604X)   N                           M                      NM                            
  CA636ATV                                                                              TVALGD      Proximal   MSI-H      NI, NI            IC            c.4024T\>G (p.L1342V)                 N                            N                       N                      c.38G\>A (p.G13D)           M                      NM                            
   PH5                                                                                  A193        A193AT     TALGD      Proximal          MSI-L         N, D17S250                            IC                           c.4189G\>A (p.E1397K)   N                      N                           N                      N                    M        *MSH6*
  A193ATV                                                                               TVAHGD      Rectum     MSS        D2S123, N         Yes           c.4123C\>T (p.H1375Y)                 N                            N                       N                      c.35G\>A (p.G12D)           M                      NM                            
  A193C                                                                                 Ca          Proximal   MSS        D2S123, D17S250   Yes           N                                     N                            N                       N                      N                           M                      NM                            
  A193PH1                                                                               HP          Proximal   MSS        D2S123, N         Yes           LOH, c.4123C\>T (p.H1375Y)            N                            N                       N                      N                           M                      NM                            
  A193PH2                                                                               HP          Proximal   MSS        D2S123, D17S250   Yes           NC                                    N                            N                       N                      N                           M                      NM                            
   PH7                                                                                  A759        A759T      Ca         Proximal          MSI-H         NI, N                                 IC                           N                       c.133T\>C (p.S45P)     c.l994delG (p.G665AfsX24)   N                      c.34G\>A) (p.G12S)   NM       NM
   PH8                                                                                  A760        A643PA     HP         Proximal          MSS           NI, N                                 No                           N                       N                      N                           c.1799T\>A (p.V600E)   N                    M        NM
  A643PB                                                                                HP          Distal     MSS        NI, N             No            N                                     N                            N                       c.1799T\>A (p.V600E)   N                           M                      NM                            
  A760AS1                                                                               TSALGD      Proximal   MSS′       NC, NC            Yes           LOH                                   N                            N                       c.1799T\>A (p.V600E)   N                           --                     --                            
  A760PH1                                                                               SSA         NA         MSI-L      NI, D17S250       --            c.3926_3930 delAAAGA (p.E1309DfsX2)   N                            N                       N                      N                           NM                     NM                            
  A760PH2                                                                               SSA         Proximal   MSI-H      NI, NC            Yes           NC                                    N                            N                       N                      N                           --                     --                            
  A760PH3                                                                               SSA         Proximal   MSI-L      NI, N             Yes           LOH                                   c.130C\>T (p.P44S)           N                       c.1799T\>A (p.V600E)   N                           NM                     NM                            
  A760PH4                                                                               SSA         NA         MSI-L      NI, NC            Yes           LOH                                   N                            N                       N                      N                           NM                     NM                            
  A760PH5                                                                               SSA         NA         MSI-L      NI, N             No            LOH                                   N                            N                       N                      N                           NM                     NM                            
  A760PH6                                                                               SSA         NA         MSS        NI, N             No            LOH                                   N                            N                       N                      N                           NM                     NM                            
  Preferential location of lesions - distal                                                                                                                                                                                                                                                                                                                  
   PH6                                                                                  A478        A478PA2    HP         NA                MSS           N, N                                  No                           N                       N                      N                           c.1799T\>A (p.V600E)   N                    M        NM
  A478PB                                                                                HP          NA         MSS        N, N              --            N                                     N                            N                       c.1799T\>A (p.V600E)   N                           *--*                   --                            
  A478PC                                                                                NCM         NA         MSS        N, N              --            N                                     N                            N                       N                      c.35G\>T (p.G12V)           NM                     NM                            
  A478PD                                                                                NCM         NA         MSS        N, N              --            N                                     --                           --                      N                      --                          --                     --                            
  A478PE                                                                                HCM         NA         MSS        N, N              --            N                                     N                            N                       N                      c.35G\>A (p.G12D)           NM                     NM                            
  A478PF                                                                                TALGD       NA         MSS        N, N              --            N                                     N                            N                       N                      N                           NM                     NM                            
  A478PG                                                                                HP          NA         MSS        N, N              No            N                                     N                            N                       c.1799T\>A (p.V600E)   N                           M                      NM                            
  A478PH                                                                                HP          NA         MSS        N, N              No            N                                     N                            N                       c.1799T\>A (p.V600E)   N                           NM                     NM                            
  A462PH1                                                                               SSA         NA         MSS        N, N              No            N                                     N                            N                       c.1799T\>A (p.V600E)   N                           M                      NM                            
  A462PH2                                                                               SSA         NA         MSS        N, N              IC            N                                     N                            N                       c.1799T\>A (p.V600E)   N                           M                      NM                            
   PH12                                                                                 A758        A758C      Ca         Distal            MSI-L         NI, NC                                No                           LOH                     N                      N                           c.1799T\>A (p.V600E)   N                    M        NM
  A758PH                                                                                HP          Rectum     MSI-L      NI, D17S250       IC            LOH                                   N                            N                       c.1799T\>A (p.V600E)   N                           M                      NM                            
   PH14                                                                                 A686        A686P1A    HP         Distal            MSS           N, N                                  No                           N                       N                      N                           N                      c.35G\>A (p.G12D)    NM       NM
  A686P2B                                                                               HP          Distal     MSS        N, N              No            N                                     N                            N                       N                      c.35G\>T (p.G12V)           M                      NM                            
  A686P3C                                                                               HP          Distal     MSS        N, N              No            N                                     N                            N                       N                      c.35G\>A (p.G12D)           NM                     NM                            
  A686P4D                                                                               HP          Distal     MSS        N, N              No            N                                     N                            N                       N                      c.35G\>A (p.G12D)           NM                     NM                            
  A686P5E                                                                               HP          Distal     MSS        N, N              --            N                                     N                            N                       N                      c.35G\>T (p.G12V)           --                     --                            
   PH19                                                                                 A993        A993PH1    HP         Rectum            MSS^\*^       --                                    Yes                          NC                      c.115G\>A (p.A39T)     N                           c.1799T\>A (p.V600E)   N                    --       --
   PH33                                                                                 A983        A983PA     HP         Proximal          MSS^\*^       **--**                                No                           N                       N                      N                           c.1799T\>A (p.V600E)   N                    NM       NM
  A983PB                                                                                HP          Proximal   MSS^\*^    **--**            No            N                                     N                            N                       c.1799T\>A (p.V600E)   N                           NM                     NM                            
  A983PC                                                                                HP          Distal     MSS^\*^    **--**            No            N                                     N                            N                       c.1799T\>A (p.V600E)   N                           NM                     NM                            
  A983PD                                                                                TALGB       Distal     MSS^\*^                      No            c.4189G\>T (p.E1397X)                 N                            N                       N                      N                           NM                     NM                            

  B, Results of the molecular analysis of SE and AD lesions from patients with SPP without a family history of SPP and/or polyps/CRC in first-degree relatives                                                                                                                                                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------- -------- ---------- --------- ---------- --------- ------------ --------------------------- --------------------- --- --------------------- -------- -------- --------
  Preferential location of lesions - Proximal/whole-colon                                                                                                                                                                                                                                                                      
   PH9                                                                                                                                                           A500     A500PA1    HP        Proximal   MSS       D2S123, NI   N                           N                     N   c.l799T\>A(p.V600E)   N        NM       *MLH1*
  A500PB2                                                                                                                                                        HP       Proximal   MSS       N, NI      N         N            N                           c.l799T\>A(p.V600E)   N   NM                    NM                
   PH16                                                                                                                                                          A990     A990ASS    SSA       NA         MSS^\*^   **--**       NC                          N                     N   N                     N        M        NM
  A990PH1                                                                                                                                                        HP       Rectum     MSS^\*^   **--**     NC        N            N                           N                     N   NM                    *MSH3*            
  Preferential location of lesions - Distal                                                                                                                                                                                                                                                                                    
   PH10                                                                                                                                                          A989     A989C      Ca        Distal     MSS^\*^   **--**       NC                          N                     N   N                     N        NM       NM
   PH11                                                                                                                                                          A757     A757AS1    SCa       NA         MSS       N, N         c.4233delT (p.S1411RfsX4)   N                     N   N                     N        M        NM
   PH18                                                                                                                                                          A992     A992AS1    TSALGB    Distal     MSS^\*^   **--**       NC                          N                     N   c.l799T\>A(p.V600E)   N        **--**   **--**
  A992AS2                                                                                                                                                        TSALGB   Distal     MSS^\*^   **--**     NC        N            N                           N                     N   **--**                **--**            
   PH22                                                                                                                                                          A951     A951P1     HP        Rectum     MSS^\*^   **--**       N                           N                     N   c.l799T\>A(p.V600E)   N        NM       NM
  A951P2                                                                                                                                                         HP       Distal     MSS^\*^   **--**     N         N            N                           c.l799T\>A(p.V600E)   N   NM                    NM                

SE, serrated; AD, adenomatous; MSI, microsatellite instability; LOH, loss of heterozygosity; MMR, mismatch repair; NA, not available; MSS′, microsatellite stable (missing one marker, D2S123); NC, not completed; N, no mutation; -, not performed; M, methylated; IC, inconclusive; NM, non-methylated; MSI-H, microsatellite instability high; NI, not informative; MSI-L, microsatellite instability low; NCM, normal colonic mucosa; HCM, hyperplastic colonic mucosa; SCa, serrated carcinoma; *MSH*, mutS Homolog; SPP, serrated polyposis; CRC, colorectal cancer. MSS\*, microsatellite stable (only performed for BAT-26, due to the lack of normal tissue for this sample). *APC* missense mutations were not taken into account, although p.H1375Y and p.E1397K mutations have been predicted by *in silico* analysis to be probably pathogenic (data not shown).

###### 

Molecular characterization of lesions from patients with SPP-FHP/CRC, stratified by preferential location of the lesions in each patient.

  Molecular characterization                            Preferential location of lesions   p-value           
  ----------------------------------------------------- ---------------------------------- ----------------- ----------------------------------------------------------------
  Total Wnt gene mutations                              **14/26 (54%)**                    **4/20 (20%)**    **0.02**[b](#tfn13-ijmm-38-03-0687){ref-type="table-fn"}
  Total RAS/RAF gene mutations                          **12/30 (40%)**                    **18/20 (90%)**   **3.7×10^−4^**[b](#tfn13-ijmm-38-03-0687){ref-type="table-fn"}
    *BRAF* gene mutations                               **7/30 (23%)**                     **12/20 (60%)**   **0.0089 (χ^2^ test)**
    *KRAS* gene mutations                               5/32 (16%)                         6/20 (30%)        NS
  MSI[a](#tfn12-ijmm-38-03-0687){ref-type="table-fn"}   **15/26 (58%)**                    **2/15 (13%)**    **0.0059**[b](#tfn13-ijmm-38-03-0687){ref-type="table-fn"}
  MMR gene methylation and/or LOH of D2S123             **17/18 (94%)**                    0/11              **3.0×10^−7^**[b](#tfn13-ijmm-38-03-0687){ref-type="table-fn"}
  *MGMT* gene methylation                               19/29 (65%)                        7/17 (41%)        NS
  LOH of *MGMT* locus                                   **16/23 (70%)**                    **1/14 (7%)**     **2.2×10^−4^**[b](#tfn13-ijmm-38-03-0687){ref-type="table-fn"}

Except for one lesion, microsatellite instability (MSI), either microsatellite instability-low (MSI-L) or microsatellite instability-high (MSI-H), was detected only in dinucleotide microsatellite markers.

Fisher\'s exact test (two-sided). SPP, serrated polyposis; CRC, colorectal cancer; SPP-FHP/CRC, SPP associated with a family history of SPP and/or polyps/CRC (multiple or diagnosed at a young age) in first-degree relatives; MMR, mismatch repair; LOH, loss of heterozygosity; *MGMT*, O-6-methylguanine-DNA methyltransferase. Statistically significant values are shown in bold. NS, non-significant (p\>0.05).

###### 

Molecular characterization of SPP-FHP/CRC lesions stratified by histological type of lesions and the preferential location of the lesions in each patient (proximal/whole-colon or distal).

                                              HCM   HP                                                               TSA                                                             SSA                                                            SCa   SE lesions                                                                                                         TA          TVA         Ca          AD lesions                                                       SE+AD lesions
  ------------------------------------------- ----- ---------------------------------------------------------------- --------------------------------------------------------------- -------------------------------------------------------------- ----- ------------------------------------------------------------------------------------------------------------------ ----------- ----------- ----------- ---------------------------------------------------------------- ---------------
  Total Wnt gene mutations                                                                                                                                                                                                                                                                                                                                                                                                                                                        
   Proximal/whole-colon                       --    **1/4 (25%)[a](#tfn15-ijmm-38-03-0687){ref-type="table-fn"}**    **4/4[a](#tfn15-ijmm-38-03-0687){ref-type="table-fn"}**         **6/7(86%)[a](#tfn15-ijmm-38-03-0687){ref-type="table-fn"}**   1/1   **12/16 (75%)[b](#tfn16-ijmm-38-03-0687){ref-type="table-fn"},[c](#tfn17-ijmm-38-03-0687){ref-type="table-fn"}**   1/6 (17%)   0/2         1/2 (50%)   **2/10 (20%)[b](#tfn16-ijmm-38-03-0687){ref-type="table-fn"}**   14/26 (54%)
   Distal colon                               0/1   2/14 (14%)                                                       --                                                              0/2                                                            --    **2/17 (12%)[c](#tfn17-ijmm-38-03-0687){ref-type="table-fn"}**                                                     1/2 (50%)   --          1/1         2/3 (67%)                                                        4/20 (20%)
  Total RAS/RAF gene mutations                                                                                                                                                                                                                                                                                                                                                                                                                                                    
   Proximal/whole-colon                       --    **2/6 (33%)**                                                    4/5 (80%)                                                       1/7 (14%)                                                      1/1   **8/19 (42%)[d](#tfn18-ijmm-38-03-0687){ref-type="table-fn"}**                                                     1/6 (17%)   2/2         1/3 (33%)   4/11 (36%)                                                       12/30 (40%)
   Distal colon                               1/1   **14/14**                                                        --                                                              2/2                                                            --    **17/17[d](#tfn18-ijmm-38-03-0687){ref-type="table-fn"}**                                                          0/2         --          1/1         1/3 (33%)                                                        18/20 (90%)
  *BRAF* gene mutations                                                                                                                                                                                                                                                                                                                                                                                                                                                           
   Proximal/whole-colon                       --    2/6 **(33%)**                                                    3/5 (60%)                                                       1/7 (14%)                                                      0/1   **6/19 (32%)[e](#tfn19-ijmm-38-03-0687){ref-type="table-fn"}**                                                     1/6 (17%)   0/2         0/3         1/11 (9%)                                                        7/30 (23%)
   Distal colon                               0/1   9/14 **(64%)**                                                   --                                                              2/2                                                            --    **11/17 (65%)[e](#tfn19-ijmm-38-03-0687){ref-type="table-fn"}**                                                    0/2         --          1/1         1/3 (33%)                                                        12/20 (60%)
  *KRAS* gene mutations                                                                                                                                                                                                                                                                                                                                                                                                                                                           
   Proximal/whole-colon                       --    0/6                                                              1/6 (17%)                                                       0/8                                                            1/1   **2/21 (10%)[f](#tfn20-ijmm-38-03-0687){ref-type="table-fn"}**                                                     0/6         2/2         1/3 (33%)   3/11 (27%)                                                       5/32 (16%)
   Distal colon                               1/1   **5/14(36%)**                                                    --                                                              0/2                                                            --    **6/17 (35%)[f](#tfn20-ijmm-38-03-0687){ref-type="table-fn"}**                                                     0/2         --          0/1         0/3                                                              6/20 (30%)
  MSI                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
   Proximal/whole-colon                       --    **1/5 (20%)[g](#tfn21-ijmm-38-03-0687){ref-type="table-fn"}**    **3/4 (75%)[g](#tfn21-ijmm-38-03-0687){ref-type="table-fn"}**   **6/7(86%)[g](#tfn21-ijmm-38-03-0687){ref-type="table-fn"}**   0/1   **10/17 (59%)[h](#tfn22-ijmm-38-03-0687){ref-type="table-fn"}**                                                    3/4 (75%)   1/2 (50%)   1/3 (33%)   5/9 (56%)                                                        15/26 (58%)
   Distal colon                               0/1   1/10(10%)                                                        --                                                              0/2                                                            --    **1/13 (8%)[h](#tfn22-ijmm-38-03-0687){ref-type="table-fn"}**                                                      0/1         --          1/1         1/2 (50%)                                                        2/15 (13%)
  MMR gene methylation and/or LOH of D2S123                                                                                                                                                                                                                                                                                                                                                                                                                                       
   Proximal/whole-colon                       --    **4/4**                                                          4/4                                                             2/2                                                            0/1   **10/11 (91%)[i](#tfn23-ijmm-38-03-0687){ref-type="table-fn"}**                                                    4/4         1/1         2/2         7/7                                                              17/18 (94%)
   Distal colon                               0/1   **0/7**                                                          --                                                              0/2                                                            --    **0/10[i](#tfn23-ijmm-38-03-0687){ref-type="table-fn"}**                                                           0/1         --          --          0/1                                                              0/11
  *MGMT* gene methylation                                                                                                                                                                                                                                                                                                                                                                                                                                                         
   Proximal/whole-colon                       --    6/6[j](#tfn24-ijmm-38-03-0687){ref-type="table-fn"}              3/4 (75%)                                                       1/7 (14%)                                                      1/1   11/18(61%)                                                                                                         4/6 (67%)   2/2         2/3 (67%)   8/11 (73%)                                                       19/29 (65%)
   Distal colon                               0/1   **4/11 (36%)**[j](#tfn24-ijmm-38-03-0687){ref-type="table-fn"}   --                                                              2/2                                                            --    6/14 (43%)                                                                                                         0/2         --          1/1         1/3 (33%)                                                        7/17(41%)
  LOH of *MGMT* locus                                                                                                                                                                                                                                                                                                                                                                                                                                                             
   Proximal/whole-colon                       --    **4/6 (67%)[k](#tfn25-ijmm-38-03-0687){ref-type="table-fn"}**    3/4 (75%)                                                       3/5 (60%)                                                      0/1   **10/16 (63%)[l](#tfn26-ijmm-38-03-0687){ref-type="table-fn"}**                                                    3/4 (75%)   1/1         2/2         6/7 (86%)                                                        16/23 (70%)
   Distal colon                               --    **1/11 (9%)[k](#tfn25-ijmm-38-03-0687){ref-type="table-fn"}**    --                                                              0/1                                                            --    **1/12 (8%)[l](#tfn26-ijmm-38-03-0687){ref-type="table-fn"}**                                                      0/1         --          0/1         0/2                                                              1/14 (7%)

Statistically significant values are shown in bold.

p=0.02, Fisher\'s exact test (2×3).

p=0.0091, Fisher\'s exact test (two-sided).

p=0.0011, Fisher\'s exact test (two-sided).

p=1.3×10^−4^, Fisher\'s exact test (two-sided).

p=0.049, Fisher\'s exact test (two-sided).

p=0.062, Fisher\'s exact test (two-sided).

p=0.017, Fisher\'s exact test (2×3).

p=0.0049, Fisher\'s exact test (two-sided).

p=3.12×10^−5^, Fisher\'s exact test (two-sided).

p=0.017, Fisher\'s exact test (two-sided).

p=0.027, Fisher\'s exact test (two-sided).

p=0.0045, Fisher\'s exact test (two-sided). SPP, serrated polyposis; CRC, colorectal cancer; SPP-FHP/CRC, SPP associated with a family history of SPP and/or polyps/CRC (multiple or diagnosed at a young age) in first-degree relatives; MMR, mismatch repair; HCM, hyperplastic colonic mucosa; HP, hyperplastic polyp; TSA, traditional serrated adenoma; TVA, tubulovillous adenoma; SSA, sessile serrated adenoma; TA, tubular adenoma; AD, adenomatous; Ca, carcinoma; SCa, serrated carcinoma; SE, serrated; LOH, loss of heterozygosity.
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